recombinant luteinizing hormone

also known as r-LH

today NCT01339299 · Ph 4

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT01339299	Oct 2009 → Jul 2012	infertility disorder	Regionshospitalet Viborg, Skive	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT00553293 Comparator	Aug 2003 → Nov 2004	infertility disorder	Rigshospitalet, Denmark	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	recombinant luteinizing hormone	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00553293 ↗ 1 NCT01339299 ↗
Known as	r-LH	“recombinant luteinizing hormone (r-LH)” NCT01339299 ↗
Modality	Protein / enzyme biologic	“addition of human LH hormone (Luveris)” NCT00553293 ↗
Route	Subcutaneous	“administration of r-LH 150 IU/day subcutaneously” NCT01339299 ↗